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Abstract
Background/Aims: Pharmacological and morphological
studies suggest that the gut mucosal immune system
and local neuropeptide-containing neurones interact.
We aimed to determine whether gut immune cells are
targets for calcitonin gene-related peptide (CGRP), which
has potent immune regulatory properties. Methods: Us-
ing density gradient centrifugation, rat lamina propria
mononuclear cells (LP-MNCs) and intra-epithelial lym-
phocytes (IELs) were isolated. RT-PCR was employed for
the detection of mRNA of rat calcitonin receptor-like
receptor (CRLR), which is considered to represent the
pharmacologically defined CGRP receptor-1 subtype, as
well as mRNA of the receptor activity-modifying pro-
teins, which are essential for CRLR function and deter-
mine ligand specificity. A radioreceptor assay was em-
ployed for the detection of specific CGRP binding sites.
Results: RT-PCR and DNA sequencing showed that LP-
MNCs and IELs express CRLR. Incubation of isolated LP-
MNCs with radiolabelled ·CGRP revealed the existence
of specific binding sites for CGRP. Conclusion: These
novel data indicate that mucosal immune cells of the rat
gut are a target for CGRP and provide significant evi-
dence that CGRP functions as an immune regulator in
the gut mucosa.
Copyright © 2002 S. Karger AG, Basel
Introduction
The gastrointestinal tract plays a unique and vital
immunological role [1]. The gut contains several neuro-
peptides that are known to have immune regulatory
actions in other tissues, and there is a lot of evidence that
peptide-containing neurones may play a role in regulating
gut immunity [2–5]. For example, Peyer’s plaques, which
are the primary lymphoid tissue of the gut mucosa, and
the lamina propria, which contains many immune cells
and is the effector site of the gut immune system, are sup-
plied by nerves that contain neuropeptides that are known
to exert potent effects on immune cells [6].
In particular, the neuropeptides substance P and calci-
tonin gene-related peptide (CGRP), which are present in
gut neurones, have been identified as probable neuroen-
docrine mediators of the neural control of immune and
inflammatory processes in several pathophysiological
models in different organs, including the gut [7–10]. Their
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activated release from sensory neurones and their media-
tion of neurogenic inflammation has been particularly
well established in a number of tissues [11, 12]. Both pep-
tides are thought to contribute to inflammatory reactions
via effects on the local blood flow – both are potently
vasodilatory, and, additionally, substance P stimulates
extravasation [13]. There is also considerable evidence
that they both act directly on immune cells; from the
numerous pharmacological studies, it appears that sub-
stance P promotes inflammatory reactions while CGRP
dampens these processes [10].
There is generally limited information concerning the
distribution of neuropeptide receptors on immune cells,
particularly those of the gut [14, 15], and this is hindering
progress in understanding the role of neuropeptides in
neuro-immune reactions. The only cloned receptor pro-
tein that has so far been identified as a receptor for CGRP
is the calcitonin receptor-like receptor (CRLR) [16].
CRLR is a G-protein-associated, seven trans-membrane
receptor that has been shown to correspond to the phar-
macologically defined CGRP receptor-1 subtype [17] and
which appears to be widely distributed in the body.
Both CGRP and adrenomedullin can act via CRLR,
but the ligand specificity of the receptor is determined by
the co-expression of particular accessory proteins, recep-
tor activity-modifying protein (RAMP)-1, -2 and -3 [18,
19]. CRLR needs to associate with a RAMP protein in
order to function as a membrane receptor. The molecular
interaction of CRLR with RAMP-1 generates a functional
CGRP receptor, while the interaction of CRLR with
RAMP-2 or RAMP-3 provides a functional and specific
adrenomedullin receptor [19].
Here, we describe experiments that were conducted to
determine whether CGRP receptors are expressed on gut
immune cells. Using radiolabelled CGRP in autoradio-
graphic analysis of rat intestine, we have previously dem-
onstrated the existence of specific CGRP binding sites in
several mucosal and submucosal areas [20]. Particularly
dense staining was obtained in the lamina propria. How-
ever, such studies do not allow resolution at the cellular
level.
In order to obtain definitive evidence of the expression
of CGRP receptors by gut immune cells, we have com-
bined molecular and biochemical analysis of isolated lam-
ina propria mononuclear cells (LP-MNCs) and intra-epi-
thelial lymphocytes (IELs) from the rat. In this work, we
obtained novel evidence of the expression of the mRNAs
of CRLR and RAMP-1, -2 and -3 and of the presence of
specific CGRP binding sites in gut mucosal immune
cells.
Materials and Methods
Animals
Adult male Wistar rats were used in all experiments.
Cell Isolation
IELs were isolated by a technique originally described by Kearsey
and Stadnyk [21]. Briefly, the entire small intestine was removed
from 4–8 rats (depending on required cell number) and the lumen
was washed with calcium- and magnesium-free Hanks’ balanced salts
solution. All Peyer’s patches and adherent mesentery were excised
with a scalpel and the intestines were opened longitudinally before
being cut into two pieces and vortexed in PBS-DTT to remove mucus
and cell debris. The epithelium with the IELs was dissected from the
underlying mucosa by vortexing the cells in RPMI-FCS-PS-HEPES
medium. Purification of IELs from the cell suspension was per-
formed to release lymphocytes from clumps of epithelium, by centri-
fugation of the cells through Percoll (see below).
To isolate LP-MNCs, the treated tissue received three more
45-min incubations with EDTA, and the released cells were discar-
ded. The remaining tissue was digested 4 times for 15 min at 37°C
in 1 mg/ml collagenase (Gibco, Eggenstein, Germany), then pressed
through a mesh sieve to free any trapped cells. LP-MNCs were puri-
fied on a discontinuous Percoll gradient (45%/75%). The cell pellet
was suspended in a 45% Percoll solution. A second 75% Percoll solu-
tion was layered under the 45% solution, and the discontinuous Per-
coll gradient was then centrifuged at 350 g for 30 min. Both cell pop-
ulations were collected from the interface between the 45% and 75%
Percoll layers and stored in RPMI-FCS-PSG-HEPES medium.
The isolated cells were counted and cell viability was determined
using trypan blue staining of cells after recovering them and washing
them free of Percoll (viability was 196%).
Antibodies Used in Phenotypic Analyses
For flow cytometry analysis, the following FITC-conjugated
monoclonal antibodies (Serotec, Wiesbaden, Germany) were used:
MRC OX-22 (anti-CD45RC), MRC OX-8 (anti-CD8), W3/25 (anti-
CD4) and MRC OX-33 (anti-CD45, B cell form).
Staining and Flow Cytometry
For single-colour immunofluorescence, 1 ! 106 cells were incu-
bated in 100 Ìl of a saturating concentration of FITC antibody in
PBS with 0.5% bovine serum albumin (BSA) for 30 min at 4°C, with
frequent mixing. After incubation, cells were washed twice, resus-
pended in 500 Ìl of PBS-BSA and analysed on a Becton Dickinson
FACScan flow cytometer. Results were generated using the FACScan
Research computer software program. Cells from the entire contour
plot were examined for fluorescence. The percentage of cells labelled
by each monoclonal antibody was calculated in comparison with cells
stained with an isotype control antibody.
Preparation of CGRP Solutions
CGRP was dissolved in sterile PBS-BSA. Stock solutions were
aliquoted at 10–4 M in Minisorb tubes (NUNC GmbH & Co, Wies-
baden, Germany) and frozen at –70°C until use. Working concentra-
tions were also prepared in Minisorb tubes.
RT-PCR
Total RNA was isolated by phenol-chloroform extraction of
guanidium-isothiocyanate lysates according to the protocol of the
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Table 1. Primers for RT-PCR
Gene Sequence Position
nucleotides
PCR
product, bp
CRLR
Forward primer
Reverse primer
5)GACATCCAGATAGTAACAGG-3)
5)CAATGCCAAGTAGTGGTACC-3)
1016–1035
1720–1701
705
RAMP-1
Forward primer
Reverse primer
5)CAATCCGGAAGTGGACAAGT-3)
5)ACACCTACACGATGCCCTCT-3)
271–290
467–448
197
RAMP-2
Forward primer
Reverse primer
5)TACAGCAACCTGCGGTATTG-3)
5)AGGAAAGGGATGAGGCAGAT-3)
315–334
517–498
203
RAMP-3
Forward primer
Reverse primer
5)TCTTGTTGACCGTGGCTATG-3)
5)CTGGGCGACATTCTTCTAGC-3)
409–428
528–509
120
NK-1 receptor
Forward primer
Reverse primer
5)CATCGTGGTGACTTCCGTGG-3)
5)GAGGCAGGAAGTAGATCAGT-3)
700–719
1202–1183
504
NK-3 receptor
Forward primer
Reverse primer
5)AGCGAGTGGTACTTTGGCG-3)
5)GACATCCAGATAGTAACAGG-3)
632–650
1078–10
447
The primers were designed based on the published cDNA sequences of rat CRLR, rat
RAMP-1, rat RAMP-2, rat RAMP-3, rat NK-1 receptor and rat NK-3 receptor (GenBank
accession Nos. L27487, AF1550, AF181551, AF181552, NM012667 and NM017053, re-
spectively).
manufacturer (Qiagen, Hilden, Germany) and treated with deoxyri-
bonucleases (MBI Fermentas, St. Leon-Rot, Germany) for 15 min at
37°C before converting into cDNA. For the RT step, 1 Ìg of total
RNA was incubated in a final volume of 20 Ìl containing 200 U of
MMV reverse transcriptase, then stored at –20°C until required for
PCR. PCR amplification was performed in a final volume of 50 Ìl
containing 1.5 ÌM MgCl2, 50 ÌM dNTPs, 0.1 ÌM of each primer and
1 U of AmpliTaq polymerase (Perkin Elmer, Überlingen, Germany).
Negative controls were performed by either omitting the reverse
transcriptase from cDNA synthesis or by omitting cDNA from the
PCR amplifications. Product specificities were confirmed by DNA
sequence analysis using an ABI Prism Genetic Analyzer (Perkin El-
mer). Sequences of all the primers used in this work are listed in
table 1.
Radioligand Binding
125I-[His10]·-CGRP was prepared with a modification of the
radioiodination procedure that has been previously employed [22].
Briefly, oxidative conditions were used (employing Iodogen, from
Pierce, Rockford, Ill., USA) at pH 8.5 in order to facilitate iodination
of histidine. The reaction mixture was then fractionated using
reversed-phase HPLC, and pure monoiodinated peptide with a spe-
cific activity of greater than 2,000 Ci/mmol was obtained.
5 ! 106 to 1 ! 107 IELs or LP-MNCs were incubated, in dupli-
cate, with 150,000–250,000 cpm of 125I-[His10]·-CGRP (150–
200 pM ) in HBSS-HEPES-0.1% BSA (final volume of 0.25 ml). Spe-
cific binding was defined as the difference between total and non-
specific binding, which was determined separately and in duplicate
by including unlabeled CGRP at a final concentration of 10–6 M in
the incubation mixture. After incubation for 1 h at RT, cells were
centrifuged for 5 min at 10.000 g at 4°C. Cells were resuspended in
ice-cold incubation buffer. Each suspension was then transferred to
fresh tubes and centrifuged again, before the cell pellet was counted
using an automatic Á-counter. SK-N-MC-cells, which are a clonal cell
line that express the CRLR [23], were used as a positive control.
Results
Isolation of Gut Mucosal Immune Cells
LP-MNCs and IELs were isolated from rat intestine.
The average yield of LP-MNCs was 1 B 1 ! 107 cells per
rat (n = 10), and for IELs, it was 5 B 1 ! 106 cells per rat
(n = 15). Isolated cells were consistently greater than 95%
viable, and any dead cells were typically large non-lym-
phocytes. Flow cytometry of the entire population recov-
ered from the 45–75% Percoll interface revealed a nearly
pure lymphocyte fraction for both fractions (195% of cells
were CD45 positive; fig. 1). The IEL preparation con-
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intra-epithelial lymphocytes (IEL)
cells allone CD45 CD4
CD8 OX33 HIS36
lamina propria mononuclear cells (LP-MNC)
cells allone CD45 CD4
CD8 OX33 HIS36
1
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Fig. 2. a Evidence of expression of CRLR
and NK receptors (Nk1R, Nk2R) in rat IELs
(lanes 1) and rat LP-MNCs (lanes 2). RT-
PCR analysis of isolated rat IELs and LP-
MNCs indicated that they express the
CGRP receptor-1 and the NK-1 receptor,
but not the NK-2 receptor. Analysis of RNA
from rat lung (lanes 3), which is known to
express all three receptors, served as the con-
trol. b Evidence of expression of RAMP-1,
-2 and -3 (R1, R2 and R3, respectively) in rat
IELs and rat LP-MNCs.
tained mostly CD8-positive cells (75–80%), a few CD4-
positive cells (20–25%) and !5% B lymphocytes. The LP-
MNC preparation contained a higher level of CD4-posi-
tive cells than CD8-positive cells (ratio 2.5:1) and 125%
B lymphocytes.
RT-PCR Analysis
In order to determine whether rat LP-MNCs and IELs
express the mRNAs for CRLR and RAMP-1, -2 and -3,
we performed RT-PCR using specific primers (table 1).
Ethidium bromide staining of the RT-PCR products from
rat LP-MNCs and IELs are shown in figure 2a and b. For
CRLR and neurokinin (NK)-1 receptor, the respective
amplification of both IEL and LP-MNC mRNAs showed
a single major visible band of approximately 705 bp (for
CRLR) and 504 bp (for NK-1 receptor). These corre-
spond to the sizes of the expected amplified cDNAs, as do
the single bands found in the parallel RT-PCR analysis of
mRNA from rat lung, which is a tissue known to express
both CRLR and NK-1 receptor [24]. No NK-3 receptor
Fig. 1. Characterisation by FACS analysis of isolated rat IELs and
LP-MNCs using fluorescent-labelled antibodies directed against
characteristic cell surface marker proteins (see Materials and Meth-
ods).
cDNA could be amplified from IEL and LP-MNC
mRNAs, in contrast to the amplified cDNA from rat lung.
Figure 2b shows that, for each of the three RAMPs, single
major bands of the expected size were detected: for
RAMP-1, 197 bp, for RAMP-2, 203 bp, and for RAMP-3,
120 bp. Reverse-transcribed ß-actin cDNA was used as
internal control for comparison between samples. To fur-
ther confirm the specificity of the amplified RT-PCR
product, sequence analysis of the CRLR transcript in LP-
MNCs and IELs was performed (data not shown).
Radioligand Binding Studies
Using a protocol with which high-affinity binding of
125I-[His10]·-CGRP on SK-N-MC cells could be demon-
strated, we were able to show that 0.5–1.0 ! 107 LP-
MNCs bind a detectable amount of 125I-[His10]·-CGRP
present at a concentration of 150–200 pM. This repre-
sents binding of high affinity and was significantly dis-
placed by CGRP but not by substance P (fig. 3).
Discussion
It has become apparent in recent years that a major
component of the body’s immune system resides in the
gut and that the enteric immune system exhibits some
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Fig. 3. Binding of 125I-·CGRP on LP-MNCs isolated from the rat
gut. The amount of 125I-·CGRP bound is shown as counts per min-
ute (cpm) for 125I-·CGRP (tracer) alone, in the presence of ·CGRP
(1 ÌM ) and in the presence of substance P (SP; 1 ÌM ).
unique and important features [25]. In particular, it is evi-
dent that the gut mucosal immune system is normally in
an activated state. The notion that the gut immune cells
are under neural influence is mostly supported by mor-
phological studies that have revealed that neuropeptide-
containing nerve endings are in close proximity to gut
mucosal immune cells [2, 4]. Neuropeptides such as
CGRP and substance P are known to have immune regu-
latory effects. It has been shown that CGRP has direct
effects on immune cells isolated from the skin [26], from
lymph nodes [27] and from the thymus and spleen [28],
but not so far in the gut. Following our observation that
the lamina propria of the rat gut contains high levels of
binding sites for CGRP [20], here we provide the first evi-
dence that immune cells of the lamina propria, as well as
IELs, express receptors for CGRP, which is novel evi-
dence that gut immune cells are indeed targets for
CGRP.
First of all, we were able to demonstrate, by FACS
analysis, that we obtained a pure lymphocyte fraction
(over 95% of the cells were CD45 positive). The FACS
analysis also confirmed already published data that the
IEL preparation contains mostly CD8-positive cells
whereas the LP-MNC preparation contains a higher level
of CD4-positive cells [25]. Employing RT-PCR and se-
quence analysis of the resulting single DNA product, we
obtained novel evidence that CRLR mRNA is expressed
by both LP-MNCs and IELs of the rat. We have also
shown here by RT-PCR that gut mucosal immune cells of
the rat express the substance P receptor (NK-1 receptor),
which confirms what has already been shown in human
[14] and mouse [15] gut immune cells. This supports the
notion that substance P may play a special role in gut
immunity [6] and indicates that our findings with CRLR
should be extended to CGRP and its role in gut immu-
nity.
The RAMPs are accessory proteins that are necessary
for CRLR to function as a receptor, and they also deter-
mine the receptor’s ligand specificity [19]. The detection
of the three RAMP mRNAs in both LP-MNC and IEL
extracts means that there may be different functional
forms of CRLR present. The co-expression of RAMP-1
allows CRLR to function as a CGRP receptor. Using a
protocol with which high-affinity binding of 125I-·CGRP
could be demonstrated, we showed that LP-MNCs bind
125I-·CGRP. The specificity of the binding was demon-
strated by its displacement by non-radiolabelled ·CGRP.
Since these experiments required such a high amount of
cells, the yield of cells from a single preparation of 8 rats
was insufficient to allow full analysis of the kinetics of
binding. Also, no binding could be demonstrated in IELs.
Both LP-MNCs and IELs are heterogenous populations of
immune cells, and it is very possible that only a subpopu-
lation of each cell fraction expresses binding sites, which
further reduces the effectiveness of such radioligand bind-
ing studies.
The co-expression of RAMP-2 and RAMP-3 with
CRLR suggests the presence of functional adrenomedul-
lin receptors [19]. Adrenomedullin and CGRP have a
similar molecular structure and biological activity. Like
CGRP, adrenomedullin is present in the healthy gastroin-
testinal tract but is actually present at much lower levels
[29]. However, there are increased levels of adrenomedul-
lin in the gut during inflammatory states, such as in sepsis
[30]. This is also reported to occur in other tissues, as well
as the fact that adrenomedullin is inducible in macro-
phages [31]. Therefore, it would be of interest, in further
studies, to investigate the possible presence of functional
adrenomedullin receptors on gut mucosal immune cells.
LP-MNCs represent the ‘effector’ arm of the gut muco-
sal immune system, which is considered to be in a state of
‘physiological’ inflammation [32]. In addition to being in
an ‘activated state’, which is, for example, evident from
the high level of expression of IL-2 and its receptor by
lamina propria immune cells, the gut immune system
exhibits an ‘active’ non-responsiveness that is vital in
order to avoid reactions to non-harmful antigens that are
derived from the gut flora and diet. In other tissues and in
different experimental models, pharmacological studies
have revealed that CGRP potently dampens immune
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responses [28, 33, 34]. Therefore, CGRP may play a simi-
lar role in the gut mucosa and contribute to the tight regu-
lation of immunity in the healthy gut mucosa by acting
directly on immune cells.
In light of our results, it would be appropriate to inves-
tigate the direct effects of this neuropeptide on gut muco-
sal immune cells under both healthy and inflammatory
conditions. The innervation of the gut mucosa plays a
vital role in regulating the function [5] and structural
integrity [35] of the gut mucosa and this is likely to
include effects on the gut immune system. CGRP can be
considered a major candidate mediator of the endocrine
control of gut immunity.
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